Paul Stoffels, Galapagos CEO (Michael Kovac/Getty Images)
June 21, 2022 04:01 PM EDTUpdated June 22, 10:54 AM
Deals

Gala­pa­gos CEO Paul Stof­fels bets €225M on a new CAR-T strat­e­gy for the long suf­fer­ing biotech

John Carroll

Editor & Founder

Tyler Patchen

News Reporter

The deeply trou­bled Eu­ro­pean biotech Gala­pa­gos and its new CEO Paul Stof­fels are go­ing the CAR-T route, and they have a new, €225 mil­lion buy­out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times